http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0970071-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5929f2d6f4dba84be8dd3a8ba633db12 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 |
filingDate | 1998-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c1404919a0624974dc21e7709f2f313f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fa091dea336bce3fec678f81dfbc5c70 |
publicationDate | 2000-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | EP-0970071-A1 |
titleOfInvention | 2-peperazinone-1-acetic acid derivatives and their use |
abstract | The present invention provides compounds and medicines effective for prophylaxis and therapy of various diseases by controlling or inhibiting cell-adhesion. Especially, the compounds of this invention inhibits platelet aggregation action without remarkable elongation or hemorrhagic period and can be used as a safe and long-acting antithrombotic drug as compared with known substances showing the same activity. Compounds of this invention are piperazinones of formula (I), wherein the ring A is a basic heterocyclic group; the ring B is a nitrogen containing heterocyclic group or a cyclic hydrocarbon group; Y is CH2; R1 is H, OH, NH¿2? or a hydrocarbon group which may be bound through CO, S, SO or SO2; R?2¿ is H or a hydrocarbon group; R3 is an optionally esterified or amidated carboxyl group; and D is a lower alkyl group substituted with an optionally esterified carboxyl group; or a salt thereof. |
priorityDate | 1997-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1244.